Dr. Samuel Funt, MD – New York, NY

Overview of Dr. Funt

Dr. Samuel Funt is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan-Kettering Cancer Center, Memorial Hospital for Cancer and allied Diseases, Memorial Hospital for Cancer and allied Diseases, and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Emory University School of Medicine and has been in practice 7 years. He is one of 468 doctors at Memorial Sloan-Kettering Cancer Center and one of 82 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He also speaks multiple languages, including Spanish. He has more than 60 publications and over 500 citings.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2016
New York Presbyterian Hospital (Columbia Campus)Chief Residency, Internal Medicine, 2013 - 2014
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2010 - 2013
Emory University School of MedicineClass of 2010

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2025
CT State Medical License 2023 - 2024
PA State Medical License 2022 - 2024
NY State Medical License 2011 - 2024
NC State Medical License 2021 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2013-2016

Clinical Trials

Publications & Presentations

PubMed

Ototoxicity associated with high-dose carboplatin for patients with previously treated germ cell tumors.
Samuel A Funt, Andrea Knezevic, Kaamilah Wilson, Maria Bromberg, Amy Budnick, Kerri L O'Connor, Deaglan J McHugh, Erik Larsen, Dean F Bajorin, Robert J Motzer, Emily S...> ;Cancer. 2023 Dec 15
1 citations
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
Brendan J Guercio, Michal Sarfaty, Min Yuen Teo, Neha Ratna, Cihan Duzgol, Samuel A Funt, Chung-Han Lee, David H Aggen, Ashley M Regazzi, Ziyu Chen, Michael Lattanzi, ...> ;Clinical Cancer Research. 2023 Nov 14
Primary Retroperitoneal Lymph Node Dissection for Seminoma Metastatic to the Retroperitoneum.
Richard S Matulewicz, Nicole Benfante, Samuel A Funt, Darren R Feldman, Brett Carver, Alexander Doudt, Andrea Knezevic, Joel Sheinfeld> ;The Journal of Urology. 2024 Jan 1
Join now to see all

Lectures

A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC).
2019 ASCO Annual Meeting - 6/1/2019
Etoposide and cisplatin (EP) for metastatic good-risk germ cell tumors (GCTs): The Memorial Sloan-Kettering Cancer Center (MSKCC) experience in 944 patients (pts).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Neoadjuvant Atezolizumab–Chemotherapy ‘Worthy of Investigation’ for MIBCFebruary 14th, 2022
A Pipeline to a Medical CareerAugust 19th, 2021
Neoadjuvant Atezolizumab with Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer - Samuel A. FuntJuly 29th, 2021
Join now to see all